ArticlePsychopharmacology2026
Potential role of PPAR-γ/MCT1-related mechanisms in INT131-mediated protection against chronic stress-induced neurobehavioral dysfunction.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic unpredictable stress (CUS) is a significant contributor to neurobehavioral changes and cognitive impairment, largely driven by disruptions in cellular homeostasis, elevated corticosterone levels and altered neurotransmitter dynamics. The PPAR-γ/MCT1 pathway plays a crucial role in regulating energy balance, modulating glucose and lipid metabolism, making it a potential target for therapeutic interventions. CUS can alter the expression of PPAR-γ & MCT1 disrupting glucose and lipid metabolism contributing to metabolic dysregulation and stress -related disorders. This study investigates the neuroprotective effects of INT131, a selective PPAR-γ agonist, in mitigating CUS-induced neurobehavioral deficits through modulation of MCT1 signalling. Swiss albino mice were exposed to varied stressors over 56 days to induce CUS. Behavioral assessments including the elevated plus maze (EPM), tail suspension test (TST), sucrose preference test (SPT), and Morris Water Maze (MWM) were used to evaluate anxiety, depression-like behavior, and memory impairment. INT131 was administered orally at 5 and 10 mg/kg doses. Fluoxetine (20 mg/kg, p.o.) served as the positived neuronal architecte control. INT131 significantly alleviated CUS-induced behavioral abnormalities and normalized corticosterone, serotonin, and dopamine levels. It also attenuated oxidative stress and inflammatory cytokines, reduced acetylcholinesterase activity, and preserved neuronal architecture, as confirmed by histological analysis. Importantly, co-treatment with CHCA (100 mg/kg, i.p.), a selective MCT1 inhibitor, abolished the neuroprotective effects of INT131, indicating MCT1's mechanistic involvement. This study demonstrates that INT131 exerts robust neuroprotective effects through the PPAR-γ/MCT1 pathway and supports its potential as a candidate for managing stress-related neurobehavioral and cognitive disorders.
Indexed as
Identifiers
42554849What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.